Literature DB >> 12697440

Expression of CD94-NKG2A inhibitory receptor is restricted to a subset of CD8+ T cells.

Veronique M Braud1, Hatice Aldemir, Beatrice Breart, Walter G Ferlin.   

Abstract

Natural killer (NK)-cell receptors (NKRs) on CD8+ T cells can modulate antigen-specific T-cell activity but their function and rules that govern their expression remain unclear. Recent work has provided new insight into CD94-NKG2A expression on T cells. Whereas upregulation on the cell surface is induced following T-cell receptor (TCR) engagement, commitment to CD94-NKG2A expression is a clonal attribute. NKRs can therefore shape cytotoxic T-lymphocyte (CTL) responses and should be considered in designing vaccine therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12697440     DOI: 10.1016/s1471-4906(03)00064-4

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  23 in total

Review 1.  Qa-1, a nonclassical class I histocompatibility molecule with roles in innate and adaptive immunity.

Authors:  Peter E Jensen; Barbara A Sullivan; Lisa M Reed-Loisel; Dominique A Weber
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.

Authors:  Nadine van Montfoort; Linda Borst; Michael J Korrer; Marjolein Sluijter; Koen A Marijt; Saskia J Santegoets; Vanessa J van Ham; Ilina Ehsan; Pornpimol Charoentong; Pascale André; Nicolai Wagtmann; Marij J P Welters; Young J Kim; Sytse J Piersma; Sjoerd H van der Burg; Thorbald van Hall
Journal:  Cell       Date:  2018-11-29       Impact factor: 41.582

3.  NKG2A and CD56 are coexpressed on activated TH2 but not TH1 lymphocytes.

Authors:  Robert J Freishtat; Lindsay W Mitchell; Svetlana D Ghimbovschi; Samuel B Meyers; Eric P Hoffman
Journal:  Hum Immunol       Date:  2006-03-27       Impact factor: 2.850

4.  Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C.

Authors:  J Nattermann; G Feldmann; G Ahlenstiel; B Langhans; T Sauerbruch; U Spengler
Journal:  Gut       Date:  2005-12-01       Impact factor: 23.059

5.  The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells.

Authors:  Jacob Nattermann; Hans Dieter Nischalke; Valeska Hofmeister; Golo Ahlenstiel; Henning Zimmermann; Ludger Leifeld; Elisabeth H Weiss; Tilman Sauerbruch; Ulrich Spengler
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

6.  Human antimicrobial cytotoxic T lymphocytes, defined by NK receptors and antimicrobial proteins, kill intracellular bacteria.

Authors:  Samuel J Balin; Matteo Pellegrini; Eynav Klechevsky; Sohui T Won; David I Weiss; Aaron W Choi; Joshua Hakimian; Jing Lu; Maria Teresa Ochoa; Barry R Bloom; Lewis L Lanier; Steffen Stenger; Robert L Modlin
Journal:  Sci Immunol       Date:  2018-08-31

Review 7.  The emerging role of HLA-E-restricted CD8+ T lymphocytes in the adaptive immune response to pathogens and tumors.

Authors:  Gabriella Pietra; Chiara Romagnani; Claudia Manzini; Lorenzo Moretta; Maria Cristina Mingari
Journal:  J Biomed Biotechnol       Date:  2010-06-22

8.  Killer cell immunoglobulin-like receptor expression induction on neonatal CD8(+) T cells in vitro and following congenital infection with Trypanosoma cruzi.

Authors:  Emmanuel Hermann; Aurélie Berthe; Carine Truyens; Cristina Alonso-Vega; Rudy Parrado; Faustino Torrico; Yves Carlier; Véronique M Braud
Journal:  Immunology       Date:  2009-11-16       Impact factor: 7.397

9.  Differential induction of CD94 and NKG2 in CD4 helper T cells. A consequence of influenza virus infection and interferon-gamma?

Authors:  Christine M Graham; Jillian R Christensen; D Brian Thomas
Journal:  Immunology       Date:  2007-06       Impact factor: 7.397

Review 10.  Immunoregulatory cells for transplantation tolerance and graft-versus-leukemia effect.

Authors:  Masahiro Imamura; Junji Tanaka
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.